Reported positive (1)
- Folate Receptor Alpha in Advanced Epithelial Ovarian Cancer: Diagnostic Role and Therapeutic Implications of a Clinically Validated Biomarker
Review · Moderate evidence · May 2025
Mirvetuximab Soravtansine
Evidence at a glanceHuman · observationalMixed results⚠ Studies disagree
3 published studies tagged to this agent2 human studies approved & graded (trial, observational, or meta-analysis)
Why this grade?
Human · observational — Human observational evidence only — no trials.
- 2 human · 0 animal · 0 lab · 1 review/other
- Most authoritative study: Analysis of real world FRα testing in ovarian, fallopian tube, and primary peritoneal cancers
- Studies disagree on the reported direction (conflict flagged).
- Findings conflict across studies
- Effect sizes reported in only 2 of 3 studies
Computed deterministically from the studies’ types and reported outcomes — not written by AI, and not a claim that anything works.
Auto-discovered · not yet curatedmirvetuximab soravtansine
Educational only, not medical advice. OncoForge makes no claim that Mirvetuximab Soravtansine treats, prevents, or cures any condition, beyond what the linked studies show. Evidence levels vary; effects may not translate to people, and some compounds can cause harm. Always coordinate with your oncology team.
Simple Summary
Auto-discovered from 1 recent study; not yet curated.
Research
Where the evidence is
What has been studied, and how strong it is, by topic. A dashed cell means no studies were found for that combination — a gap, not evidence of no effect. Open a row to see its studies.
CancerHuman evidenceMechanismSafetyTrial
Epithelial Ovarian Cancer111—
- Folate Receptor Alpha in Advanced Epithelial Ovarian Cancer: Diagnostic Role and Therapeutic Implications of a Clinically Validated Biomarker ReviewReported positive
- Ocular Toxicity of Mirvetuximab Human · observationalReported negative
Fallopian Tube Cancer1—1—
- Ocular Toxicity of Mirvetuximab Human · observationalReported negative
Fallopian Tube Neoplasms11——
- Analysis of real world FRα testing in ovarian, fallopian tube, and primary peritoneal cancers Human · observationalMixed results
Ovarian Cancer11——
- Analysis of real world FRα testing in ovarian, fallopian tube, and primary peritoneal cancers Human · observationalMixed results
Primary Peritoneal Cancer1—1—
- Ocular Toxicity of Mirvetuximab Human · observationalReported negative
Primary Peritoneal Neoplasms11——
- Analysis of real world FRα testing in ovarian, fallopian tube, and primary peritoneal cancers Human · observationalMixed results
High Grade Serous Ovarian Carcinoma—1——
Ovarian Neoplasms—1——
Platinum Resistant Epithelial Ovarian Cancer—1——
Reported figures
Study mix
3 published studies by what they were done in. Lab and animal findings often do not carry over to people.
2 Human1 Review/other
Reported directionReported positive1Mixed results1Reported negative1
What supports this page
The kinds of sources behind this page, strongest at the top. Faint rungs show what is not here yet.
Guideline0
Meta-analysis0
Systematic review0
Randomized trial0
Clinical trial0
Observational2
Case report0
Review1
Preclinical0
Other0
3 studies2 human1 review/other
Tracking 3 published studies of Mirvetuximab Soravtansine: 2 in humans, 1 reviews/other.
Reported direction across studies: 1 positive, 1 mixed, 1 negative.
Findings conflict — both supportive and negative/mixed results exist (see below). Human evidence is limited.
These counts summarize what the studies reported; they are not a measure of whether Mirvetuximab Soravtansine works.
Cancers named in these studies
epithelial ovarian cancer (2)high-grade serous ovarian carcinoma (1)platinum-resistant epithelial ovarian cancer (1)ovarian neoplasms (1)ovarian cancer (1)fallopian tube neoplasms (1)primary peritoneal neoplasms (1)primary peritoneal cancer (1)fallopian tube cancer (1)
Conflicting evidence
Negative or mixed (2)
- Analysis of real world FRα testing in ovarian, fallopian tube, and primary peritoneal cancers
Human · observational · Limited evidence · Jan 2025 - Ocular Toxicity of Mirvetuximab
Human · observational · Limited evidence · Feb 2019
All studies
ReviewMechanismReported positiveModerate evidenceTier 4 · clinical
Folate Receptor Alpha in Advanced Epithelial Ovarian Cancer: Diagnostic Role and Therapeutic Implications of a Clinically Validated Biomarker
International journal of molecular sciences · May 2025 · review
Mirvetuximab-soravtansineepithelial ovarian cancerhigh-grade serous ovarian carcinomaplatinum-resistant epithelial ovarian cancerovarian neoplasms
This review summarizes the role of folate receptor alpha (FRα) in ovarian cancer, noting that FRα is frequently overexpressed in high-grade serous ovarian carcinoma. It describes that a VENTANA IHC assay is approved as a companion diagnostic to select patients (≥75% tumor cells with moderate to strong membrane staining) for the FRα-targeted antibody-drug conjugate mirvetuximab soravtansine, and discusses biological significance, IHC technical issues, and heterogeneity of expression across subtypes and tissue samples.
Key findings
- FRα is frequently overexpressed in several epithelial malignancies, particularly in high-grade serous ovarian carcinoma.
- The VENTANA FOLR1 (FOLR1-2.1) RxDx Assay (IHC) is now approved as a companion diagnostic for selecting patients eligible for mirvetuximab soravtansine.
- Clinical trials (SORAYA and MIRASOL) demonstrated significant clinical benefit in platinum-resistant epithelial ovarian cancer patients with high FRα expression (≥75% of tumor cells with moderate to strong membrane staining).
- The review summarizes biological significance of FRα in ovarian cancer progression and its predictive value for targeted therapy.
- Technical aspects of IHC assessment, including scoring interpretation and pre-analytical variables, are discussed.
- Heterogeneity in FRα expression across histological subtypes and tumor sites, and differences between archival versus fresh tissue, are important considerations.
Limitations: This is a review article and does not present new, individual patient-level data.; FRα expression heterogeneity across histologic subtypes and tumor sites may limit generalizability of biomarker-based selection.; IHC technical factors and pre-analytical variables can affect assessment of FRα and thus patient selection.; The companion diagnostic and demonstrated benefit apply specifically to patients with high FRα expression (≥75%), so findings may not extend to lower expressors..
AI summary of the abstract, human-reviewed · Jul 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
Human · observationalMechanismMixed resultsLimited evidenceTier 3 · early humann = 425
Analysis of real world FRα testing in ovarian, fallopian tube, and primary peritoneal cancers
Gynecologic oncology · Jan 2025 · retrospective study
This retrospective study looked at 425 tumor samples from people with ovarian, fallopian tube, or primary peritoneal cancers to see how often folate receptor alpha (FRα) was present. FRα was found in 36.3% of cases and was more common in high-grade serous ovarian tumors and in samples from the ovary, fallopian tube, adnexa, or dominant pelvic masses than in metastatic sites. The study also found that some patients had different FRα results in different specimens, suggesting variability in testing results across samples.
Reported effect: positive rates 44.4%, p=0.02
Key findings
- FRα was highly expressed in 36.3% of cases.
- FRα positivity was significantly associated with high-grade serous ovarian histology.
- Samples from the ovary, fallopian tube, adnexa, and dominant pelvic masses had higher FRα positivity than metastatic sites (44.4% vs 32.5%, p = 0.02).
- Time between collection and testing did not impact FRα expression.
- Among 8 patients with more than one specimen tested, 3 (37.5%) had discordant results.
Limitations: Retrospective single-study biomarker analysis.; No treatment outcomes or patient survival endpoints were reported.; Biomarker testing only; does not test mirvetuximab soravtansine efficacy.; Potential sampling and site-related heterogeneity.; Small subgroup with repeated specimens (n=8)..
Useful for understanding FRα testing patterns relevant to selecting patients for FRα-targeted therapy, but it does not evaluate anticancer efficacy.
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed
Human · observationalSafetyReported negativeLimited evidenceTier 3 · early humann = 5
Ocular Toxicity of Mirvetuximab
Cornea · Feb 2019 · case series
Supportive careMirvetuximab-soravtansineepithelial ovarian cancerprimary peritoneal cancerfallopian tube cancer
This case series describes five women receiving mirvetuximab soravtansine who developed bilateral corneal subepithelial opacities and symptoms such as blurred vision and tearing. Imaging (AS-IR and AS-OCT) showed hyporeflective, likely cystic, subepithelial lesions. With a short course of topical steroids and lubricants, all patients' corneas cleared and visual acuity fully recovered.
Reported effects: average age 62.4, n=5 · blurred vision (n) 5, n=5 · +5 more
Key findings
- All 5 patients were female (average age, 62.4 ± 5.5 years) and being treated for advanced epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.
- Both eyes were involved in each case.
- Patients complained of blurred vision (n = 5), ocular pain (n = 2), tearing (n = 5), foreign-body sensation (n = 4), and photophobia (n = 4).
- Slit-lamp examination demonstrated fine corneal subepithelial opacities, mainly involving the corneal periphery migrating toward the center.
- AS-IR revealed the presence of hyporeflective dots on the cornea, suggesting that they were cystic.
- AS-OCT confirmed the subepithelial location of lesions.
- In all patients, the cornea cleared, and visual acuity recovered fully with a short course of topical steroids and lubricants.
Limitations: Very small sample size (n = 5) from a single center (case series).; No control or comparator group.; No detailed information on mirvetuximab soravtansine dose, schedule, or timing of symptom onset relative to dosing.; No long-term follow-up reported to assess recurrence or late sequelae.; No mechanistic or histologic confirmation of the lesions beyond imaging..
AI summary of the abstract, human-reviewed · Jul 2026. Describes what this study reported, not medical advice. View on PubMed
What changed recently
The latest additions to Mirvetuximab Soravtansine's evidence base, and anything that's been retracted.
Recently added- Analysis of real world FRα testing in ovarian, fallopian tube, and primary peritoneal cancers Human · observational · added Jun 2026
- Folate Receptor Alpha in Advanced Epithelial Ovarian Cancer: Diagnostic Role and Therapeutic Implications of a Clinically Validated Biomarker Review · added Jul 2026
- Ocular Toxicity of Mirvetuximab Human · observational · added Jul 2026
Cancers where Mirvetuximab Soravtansine reported positive results
Where at least one study reported a positive result, shown with the full picture, not just the wins. Positive results are more likely to be published, and most of these are early lab or animal studies that may not translate to people. This reports what studies found, not what works.
Preclinical only: lab / animal (4)
Limitations: This is a review article and does not present new, individual patient-level data.; FRα expression heterogeneity across histologic subtypes and tumor sites may limit generalizability of biomarker-based selection.; IHC technical factors and pre-analytical variables can affect assessment of FRα and thus patient selection.; The companion diagnostic and demonstrated benefit apply specifically to patients with high FRα expression (≥75%), so findings may not extend to lower expressors..
Cited positive studies (1)
High-grade serous ovarian carcinoma1 positive
Limitations: This is a review article and does not present new, individual patient-level data.; FRα expression heterogeneity across histologic subtypes and tumor sites may limit generalizability of biomarker-based selection.; IHC technical factors and pre-analytical variables can affect assessment of FRα and thus patient selection.; The companion diagnostic and demonstrated benefit apply specifically to patients with high FRα expression (≥75%), so findings may not extend to lower expressors..
Cited positive studies (1)
Limitations: This is a review article and does not present new, individual patient-level data.; FRα expression heterogeneity across histologic subtypes and tumor sites may limit generalizability of biomarker-based selection.; IHC technical factors and pre-analytical variables can affect assessment of FRα and thus patient selection.; The companion diagnostic and demonstrated benefit apply specifically to patients with high FRα expression (≥75%), so findings may not extend to lower expressors..
Cited positive studies (1)
Ovarian neoplasms1 positive
Limitations: This is a review article and does not present new, individual patient-level data.; FRα expression heterogeneity across histologic subtypes and tumor sites may limit generalizability of biomarker-based selection.; IHC technical factors and pre-analytical variables can affect assessment of FRα and thus patient selection.; The companion diagnostic and demonstrated benefit apply specifically to patients with high FRα expression (≥75%), so findings may not extend to lower expressors..
Cited positive studies (1)
Evidence at a glance: Mirvetuximab Soravtansine by cancer
A deterministic grade of what published studies report for each: strength of evidence, the reported direction, and the largest credible effect, strongest-evidence first. This summarizes findings; it is not a claim that anything works.
Human observational evidence only — no trials.
Largest credible effect: average age 62.4, n=5 PMID 30379722 · effect sizes 2–62.4 across 7 studies
Most authoritative study: Ocular Toxicity of Mirvetuximab
Findings conflict across studies · Effect sizes reported in only 1 of 2 studies.
Human observational evidence only — no trials.
Largest credible effect: average age 62.4, n=5 PMID 30379722 · effect sizes 2–62.4 across 7 studies
Most authoritative study: Ocular Toxicity of Mirvetuximab
Based on a single study.
Fallopian tube neoplasmsHuman · observationalMixed results1 human
Human observational evidence only — no trials.
Largest credible effect: positive rates 44.4%, p=0.02 PMID 39631181
Most authoritative study: Analysis of real world FRα testing in ovarian, fallopian tube, and primary peritoneal cancers
Based on a single study.
Human observational evidence only — no trials.
Largest credible effect: positive rates 44.4%, p=0.02 PMID 39631181
Most authoritative study: Analysis of real world FRα testing in ovarian, fallopian tube, and primary peritoneal cancers
Based on a single study.
Primary peritoneal cancerHuman · observationalReported negative1 human
Human observational evidence only — no trials.
Largest credible effect: average age 62.4, n=5 PMID 30379722 · effect sizes 2–62.4 across 7 studies
Most authoritative study: Ocular Toxicity of Mirvetuximab
Based on a single study.
Primary peritoneal neoplasmsHuman · observationalMixed results1 human
Human observational evidence only — no trials.
Largest credible effect: positive rates 44.4%, p=0.02 PMID 39631181
Most authoritative study: Analysis of real world FRα testing in ovarian, fallopian tube, and primary peritoneal cancers
Based on a single study.
No primary experimental studies yet.
Most authoritative study: Folate Receptor Alpha in Advanced Epithelial Ovarian Cancer: Diagnostic Role and Therapeutic Implications of a Clinically Validated Biomarker
No human studies yet · No numeric effect sizes reported · Based on a single study.
Ovarian neoplasmsInsufficient evidenceReported positive
No primary experimental studies yet.
Most authoritative study: Folate Receptor Alpha in Advanced Epithelial Ovarian Cancer: Diagnostic Role and Therapeutic Implications of a Clinically Validated Biomarker
No human studies yet · No numeric effect sizes reported · Based on a single study.
No primary experimental studies yet.
Most authoritative study: Folate Receptor Alpha in Advanced Epithelial Ovarian Cancer: Diagnostic Role and Therapeutic Implications of a Clinically Validated Biomarker
No human studies yet · No numeric effect sizes reported · Based on a single study.
Clinical trials studying Mirvetuximab Soravtansine
0 ongoing · 2 completed · tracked from ClinicalTrials.gov. Recruiting is not the same as proven, and completed is not the same as positive — read the results. Not a recommendation.
Completed
- A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha ExpressionPrimary outcome measured: Objective Response Rate (ORR): Percentage of Participants With Objective Response as Assessed by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)
- Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer
1 stopped (terminated / withdrawn / suspended)
Inclusion here is not an endorsement. OncoForge makes no claim beyond what the linked studies show. Discuss anything on this page with your oncology team before acting on it.